The prognostic impact of the cytomegalovirus ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the infectious diseases working party of ebmt
Auteur(s) :
Schmidt-Hieber, Martin [Auteur]
Tridello, Gloria [Auteur]
Ljungman, Per [Auteur]
Mikulska, Malgorzata [Auteur]
Knelange, Nina [Auteur]
Blaise, Didier [Auteur]
Socie, Gerard [Auteur]
Volin, Liisa [Auteur]
Blijlevens, Nicole [Auteur]
Fegueux, Nathalie [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Forcade, Edouard [Auteur]
Maertens, Johan [Auteur]
Chevallier, Patrice [Auteur]
Passweg, Jakob [Auteur]
Cornelissen, Jan J. [Auteur]
Russell, Nigel [Auteur]
Craddock, Charles [Auteur]
Bourhis, Jean-Henri [Auteur]
Marchand, Tony [Auteur]
Remenyi, Peter [Auteur]
Cahn, Jean-Yves [Auteur]
Michallet, Mauricette [Auteur]
Montoto, Silvia [Auteur]
Kroger, Nicolaus [Auteur]
GlaB, Bertram [Auteur]
Styczynski, Jan [Auteur]
Tridello, Gloria [Auteur]
Ljungman, Per [Auteur]
Mikulska, Malgorzata [Auteur]
Knelange, Nina [Auteur]
Blaise, Didier [Auteur]
Socie, Gerard [Auteur]
Volin, Liisa [Auteur]
Blijlevens, Nicole [Auteur]
Fegueux, Nathalie [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Forcade, Edouard [Auteur]
Maertens, Johan [Auteur]
Chevallier, Patrice [Auteur]
Passweg, Jakob [Auteur]
Cornelissen, Jan J. [Auteur]
Russell, Nigel [Auteur]
Craddock, Charles [Auteur]
Bourhis, Jean-Henri [Auteur]
Marchand, Tony [Auteur]
Remenyi, Peter [Auteur]
Cahn, Jean-Yves [Auteur]
Michallet, Mauricette [Auteur]
Montoto, Silvia [Auteur]
Kroger, Nicolaus [Auteur]
GlaB, Bertram [Auteur]
Styczynski, Jan [Auteur]
Titre de la revue :
Annals of Hematology
Nom court de la revue :
Ann. Hematol.
Numéro :
98
Pagination :
755–1763
Date de publication :
2019-07-01
ISSN :
1432-0584
Mot(s)-clé(s) en anglais :
Serostatus
Cytomegalovirus
Survival
Allogeneic hematopoietic stem cell transplantation
Chronic hematological malignancies
Cytomegalovirus
Survival
Allogeneic hematopoietic stem cell transplantation
Chronic hematological malignancies
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
It has been shown recently that donor and/or recipient cytomegalovirus (CMV) seropositivity is associated with a significant overall survival (OS) decline in acute leukemia patients who underwent allogeneic hematopoietic ...
Lire la suite >It has been shown recently that donor and/or recipient cytomegalovirus (CMV) seropositivity is associated with a significant overall survival (OS) decline in acute leukemia patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We now analyzed the prognostic impact of the donor/recipient CMV serostatus in 6968 patients with chronic hematological malignancies who underwent allo-HSCT. Donor and/or recipient CMV seropositivity was associated with a significantly reduced 2-year progression-free survival (PFS, 50% vs. 52%, p = 0.03) and OS (62% vs. 65%, p = 0.01). Multivariate Cox regression analyses showed an independent negative prognostic impact of donor and/or recipient CMV seropositivity on PFS (HR, 1.1; 95% CI, 1.0-1.2; p = 0.03), OS (HR, 1.1; 95% CI, 1.0-1.2; p = 0.003), and non-relapse mortality (HR, 1.2; 95% CI, 1.0-1.3; p = 0.02). OS decline was strongest for CMV-seropositive recipients with a CMV-seronegative donor (HR, 1.2; 95% CI, 1.1-1.3), followed by CMV-seropositive patients with a CMV-seropositive donor (HR, 1.1; 95% CI, 1.0-1.2). Conversely, OS did not differ significantly between CMV-seronegative recipients allografted from a CMV-seropositive donor (HR, 1.0; 95% CI, 0.9-1.2) and patients with donor/recipient CMV seronegativity (p = 0.001 for the four groups together). Non-relapse mortality was also significantly (p = 0.01) higher for CMV-seropositive patients with a CMV-seronegative graft (HR, 1.2; 95% CI, 1.1-1.4) than for CMV-seropositive patients with a CMV-seropositive graft (HR, 1.1; 95% CI, 0.9-1.2) or CMV-seronegative recipients with a CMV-seropositive graft (HR, 1.0; 95% CI, 0.8-1.2). Donor and/or recipient CMV seropositivity still results in an OS decline in patients with chronic hematological malignancies who have undergone allo-HSCT. However, this OS decline seems to be lower than that described for acute leukemia patients previously.Lire moins >
Lire la suite >It has been shown recently that donor and/or recipient cytomegalovirus (CMV) seropositivity is associated with a significant overall survival (OS) decline in acute leukemia patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We now analyzed the prognostic impact of the donor/recipient CMV serostatus in 6968 patients with chronic hematological malignancies who underwent allo-HSCT. Donor and/or recipient CMV seropositivity was associated with a significantly reduced 2-year progression-free survival (PFS, 50% vs. 52%, p = 0.03) and OS (62% vs. 65%, p = 0.01). Multivariate Cox regression analyses showed an independent negative prognostic impact of donor and/or recipient CMV seropositivity on PFS (HR, 1.1; 95% CI, 1.0-1.2; p = 0.03), OS (HR, 1.1; 95% CI, 1.0-1.2; p = 0.003), and non-relapse mortality (HR, 1.2; 95% CI, 1.0-1.3; p = 0.02). OS decline was strongest for CMV-seropositive recipients with a CMV-seronegative donor (HR, 1.2; 95% CI, 1.1-1.3), followed by CMV-seropositive patients with a CMV-seropositive donor (HR, 1.1; 95% CI, 1.0-1.2). Conversely, OS did not differ significantly between CMV-seronegative recipients allografted from a CMV-seropositive donor (HR, 1.0; 95% CI, 0.9-1.2) and patients with donor/recipient CMV seronegativity (p = 0.001 for the four groups together). Non-relapse mortality was also significantly (p = 0.01) higher for CMV-seropositive patients with a CMV-seronegative graft (HR, 1.2; 95% CI, 1.1-1.4) than for CMV-seropositive patients with a CMV-seropositive graft (HR, 1.1; 95% CI, 0.9-1.2) or CMV-seronegative recipients with a CMV-seropositive graft (HR, 1.0; 95% CI, 0.8-1.2). Donor and/or recipient CMV seropositivity still results in an OS decline in patients with chronic hematological malignancies who have undergone allo-HSCT. However, this OS decline seems to be lower than that described for acute leukemia patients previously.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Date de dépôt :
2024-01-30T10:27:39Z
2024-01-30T16:09:47Z
2024-01-30T16:09:47Z